Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wintergreen Throat Spray + aspirin is an investigational combination therapy developed by Applied Biological Laboratories (under the brand Biovanta) for the treatment of common cold symptoms and pharyngitis. The regimen consists of a topical throat spray and a 325 mg oral aspirin tablet. The throat spray contains a 'Mucosal Immune Complex' (MIC) composed of wintergreen oil (methyl salicylate), menthol, lactoferrin, lysozyme, and aloe vera. Methyl salicylate and aspirin both act as cyclooxygenase (COX) enzyme inhibitors, reducing the production of inflammatory prostaglandin E2 at the respiratory epithelium. The protein components (lysozyme and lactoferrin) and aloe are included to support and protect the mucosal barrier function. This combination was evaluated in a Phase 1 clinical trial (NCT06106880) to assess its efficacy in alleviating upper respiratory inflammation and associated symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wintergreen throat spray + aspirin.